Hibiscus (Hibiscus sabdariffa) Evidence

Evidence posture

Supportive human evidence for modest blood-pressure reduction; lipid and glycemic effects are less consistent and depend on population, preparation, and outcome.

What the evidence supports

Systematic reviews and meta-analyses of randomized trials generally report reductions in systolic and diastolic blood pressure, especially in people with elevated baseline blood pressure. Lipid and glycemic findings are more variable, and long-term therapeutic-dose safety and optimal dosing remain incompletely defined.

Studied context

Trials use Hibiscus sabdariffa beverages, teas, extracts, and varying doses for several weeks or longer. Effects are population- and preparation-dependent.

Safety context

A recent umbrella review did not find an overall increase in adverse-event risk, but it emphasized that long-term and therapeutic-dose safety needs further study. Product preparation and dose remain important.

Product directness

V-ITAREN lists hibiscus ('Jamaica grass') but does not disclose the plant part, preparation, standardization, or dose. Blood-pressure trial results therefore cannot be assigned directly to the finished product.

Products that list this ingredient/category

Primary and authoritative sources

Review-level evidence highlights

Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis (Umbrella review and updated dose-response meta-analysis of randomized controlled trials; PMID 39870328)

Population/scope: 26 randomized controlled trials involving 1,797 participants

Evidence scope: Blood pressure, lipids, glycemic control, anthropometrics, inflammation, oxidative stress, liver enzymes, and safety

Finding: The updated synthesis found the most credible benefit for blood-pressure lowering, with additional favorable changes in some lipid and glycemic markers.

Limitations: Certainty and credibility varied by outcome and subgroup; long-term and therapeutic-dose safety remain incompletely characterized.

Directness: Relevant human evidence · verified 2026-10-02

Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.